# Diabetes Research Hub — Monitor Report

**Review date:** 2026-07-28 (automated run)
**Data reviewed:** Analysis/Results/ latest snapshots + gap analysis + 7-day web scan
**Reviewer note:** This is a read-only review run. No source files were modified.

---

## ⚠️ Headline (read this first)

**The daily data pipeline has been dark for 11 days.** Every `_latest` input is dated **2026-07-17** and the daily snapshot series (clinical trials + PubMed) stops at 2026-07-17. The hub_monitor.py report itself is from 2026-07-17. You are reviewing an 11-day-old picture of a fast-moving field. Nothing here is stale enough to be *wrong*, but a Phase 3 readout or FDA action in the last 11 days would not be in your local data — and per the web scan below, at least one FDA decision (Lilly efsitora) was due in this exact window.

**Fix:** re-run the three baseline scripts before trusting the trial/PubMed sections for anything time-sensitive (commands at bottom).

---

## File System Status

| File | Last modified | Age (days) | Status |
|------|--------------|-----------|--------|
| clinical_trials_latest.json | 2026-07-17 | 11 | Aging |
| pubmed_recent_latest.json | 2026-07-17 | 11 | Aging |
| literature_gap_data.json | 2026-07-18 | 10 | Aging |
| literature_gap_report.md | 2026-07-27 | 1 | Fresh |
| hub_monitor_report.md | 2026-07-17 | 11 | Aging |
| Last daily snapshot (trials + PubMed) | 2026-07-17 | 11 | **Pipeline paused** |

All expected files exist. None are yet past the 14-day staleness threshold, but four of six cross it within three days if the pipeline stays down. The 2026-07-17 hub_monitor.py run already flagged **827 result files older than 14 days**.

Note: the last hub_monitor.py run recorded its hub root under a prior session mount (`intelligent-bold-bardeen`). Cosmetic — the tracked file tree matches the current workspace.

Housekeeping (not blocking): the `.git/` directory holds hundreds of stray `HEAD.lock.*` / `index.lock.*` files. The repo's lock handling is leaving debris; worth a manual `git` cleanup when convenient.

---

## Clinical Trial Changes

Snapshot: **858 unique trials** — 269 RECRUITING, 151 NOT_YET_RECRUITING, 110 ACTIVE_NOT_RECRUITING, 321 COMPLETED. 136 Phase 3 total; **52 Phase 3 currently recruiting.**

**Change since 2026-07-10 snapshot:** 8 new trials, 2 removed, 0 status changes flagged. Low churn — consistent with a quiet window, not a broken feed. New entries worth a glance:

- **NCT07702890** (Gubra A/S) — Phase 1/2 first-in-human, not yet recruiting.
- **NCT07699380** (Univ. Washington) — Phase 2, metabolic modulation for insulin sensitivity/mitochondrial function.
- **NCT07696273** (Indiana Univ.) — breath-based sensor for hypo/hyperglycemia detection (device).

**Phase 3 trials tied to our tracked therapies (all still pre-results):**

| Therapy | Trial | Sponsor | Status | Relevance |
|---------|-------|---------|--------|-----------|
| Zimislecel / VX-880 | NCT06832410, NCT04786262 | Vertex | RECRUITING | Cornerstone stem-cell T1D cure program — no results posted yet |
| Baricitinib | NCT07222137 (delay Stage 3), NCT07222332 (preserve β-cell) | Eli Lilly | RECRUITING | Repurposed JAK inhibitor in T1D prevention — sits at intersection of Tier 1 *Drug Repurposing* + T1D immunotherapy |
| Elecoglipron | NCT07662044 / 109 / 135 / 213 | AstraZeneca | RECRUITING | **New this window** — 4 Phase 3s all started 2026-07-06 (oral GLP-1 competitor) |
| CagriSema | NCT07564414 | Novo Nordisk | RECRUITING | Phase 3, started 2026-05-21 |
| Enicepatide | NCT07351058, NCT07670416 | Roche | RECRUITING | Amylin analog, Phase 3 |
| VX-264 | NCT05791201 | Vertex | ACTIVE_NOT_RECRUITING | Encapsulated islet (immunosuppression-free) |

**Recently posted results worth reviewing (most recent):**

- **NCT05086445** — Lilly, orforglipron in Japanese T2D — results posted **2026-07-16** (a tracked key therapy).
- **NCT04255433** — Lilly, tirzepatide vs dulaglutide — results 2026-07-08.
- **NCT06010004** — Lilly, orforglipron long-term safety — results 2026-06-30.
- **NCT06340854** — Novo, basal insulin switch study — results 2026-07-02.

---

## PubMed Highlights

Snapshot: **158 unique papers**, 30-day lookback, 16 domains.

**Publication volume signal** (last 30 days, by domain):

```
Diabetes AI/ML        260  ████████████████████  HIGH
Diabetes Microbiome   186  ██████████████        HIGH
T2D GLP-1 New         167  █████████████         HIGH
Diabetes Biomarker    166  █████████████         HIGH
Health Equity          72  ██████                HIGH
Multi-Omics            65  █████                 HIGH
T2D Remission          59  █████                 HIGH
...
Drug Repurpose          8  █                     LOW
Epigenetics             5  ▌                     LOW
GLP-1 Pharmacogenomics  1  ▏                     LOW
```

The three LOW domains (Drug Repurposing, Epigenetics, GLP-1 Pharmacogenomics) are all Tier 1/Tier 2 contribution areas for us — low external output there is *opportunity*, not absence of interest.

**Key-therapy mentions:** orforglipron (5 papers), CagriSema (5), dapagliflozin (5), retatrutide (4), teplizumab (4), icodec (3), baricitinib (2). **zimislecel: 0** — the Vertex program is generating trials but not yet indexed literature; watch for the first synthesis paper.

**Cross-domain papers (highest value — 12 total). Top picks:**

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric T1D case* — spans **AI/ML + Closed Loop AP + Health Equity** (triple-domain). Directly relevant to Tier 1 equity + AI work.
- **[42419792]** *Comparative effects of drugs for adults with overweight/obesity (systematic review)* — orforglipron + retatrutide + CagriSema in one head-to-head synthesis.
- **[42459212]** / **[42458730]** — two multi-omics × microbiome papers (precision nutrition; BMI response to dietary intervention). Feed directly into Tier 1 *Multi-Omics Biomarker Integration*.
- **[42453334]** *Noncoding RNAs for diabetes biomarkers* — Biomarker × LADA crossover (LADA is otherwise a low-volume domain).

---

## Gap Analysis Summary

From `literature_gap_report.md` (regenerated 2026-07-27; **BRONZE** validation — single analytical source, needs expert confirmation). Top intersections by gap score:

| Rank | Intersection | Gap | Joint pubs | Tier 1 alignment |
|------|-------------|-----|-----------|------------------|
| 1 | Treg/CAR-T × Neuropathy | 100.0 | 0 | Literature synthesis (immunology) |
| 2 | Beta Cell Regen × Health Equity | 100.0 | 0 | **Tier 1: Epidemiology/Equity** |
| 3 | Treg/CAR-T × Health Equity | 100.0 | 0 | **Tier 1: Epidemiology/Equity** |
| 4 | Glucokinase × Health Equity | 100.0 | 0 | **Tier 1: Epidemiology/Equity** |
| 5 | Gene Therapy × LADA | 100.0 | 0 | Literature synthesis |
| (6) | Drug Repurposing × Health Equity | 100.0 | 0 | **Tier 1: Drug Repurposing + Equity** |

**Signal:** four of the top six gaps pair an emerging therapy class (cell therapy, CAR-Treg, glucokinase activators, drug repurposing) with **Health Equity** — squarely inside our Tier 1 lanes (#4 Drug Repurposing, #6 Epidemiological/Equity). This is a coherent, defensible contribution thesis: *nobody is asking who gets access to the next generation of diabetes therapies.* Recommend promoting the "emerging-therapy × equity access" cluster to a candidate synthesis project.

Caveat per Doctrine: a Gap Score of 100 with 0 joint pubs can also be a terminology artifact. Verify each with a direct combined-term PubMed search and a Cochrane/PROSPERO check before treating as a real gap.

---

## Breaking News (7-day web scan)

Genuinely significant items (evidence level noted; all EXTERNAL web sources, not yet in local data):

- **[Likely] Lilly insulin efsitora alfa (once-weekly) — FDA decision was expected July 2026.** Still listed as *pending* as of mid-2026. If it cleared in the last 11 days, your local trial data won't show it. **Action: verify status directly.** QWINT-1 showed HbA1c −1.31% vs −1.27% for glargine.
- **[Certain] Teplizumab (Tzield) — FDA approved expanded pediatric indication (ages 8–17, recently-diagnosed Stage 3 T1D) on 2026-06-12.** Predates the snapshot but reinforces the 4 teplizumab PubMed hits. Relevant to T1D immunotherapy tracking.
- **[Certain] Orforglipron (Foundayo) — FDA-approved for obesity April 2026; T2D filing in late-stage.** Consistent with the fresh NCT05086445 results posting.
- **[Likely] Breakthrough T1D grant (2026-07-07)** funding the PRISE-hATG study of SAB-142 in Stage 3 T1D — early-stage, worth tracking as a new immunotherapy entrant.
- **[Guessing] ISSCR 2026 stem-cell reports** on immune-engineered allogeneic islets surviving without chronic immunosuppression — directional, not a discrete result. Aligns with the Vertex VX-264 / encapsulation theme.

Nothing in the scan rises to a Phase 3 primary-endpoint readout that forces an immediate tracker change. The efsitora decision is the one open loop.

---

## Recommended Actions

1. **Refresh the pipeline first.** It's been paused 11 days. Run, in order:
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   - `python project1_literature_gap_analysis.py` (data is 10 days old; report was hand-regenerated 07-27 but off older data)
   - `python hub_monitor.py`
2. **Verify efsitora alfa FDA status** and, if approved, update the tracker + add to the completed/approved therapy list.
3. **Review orforglipron result posting NCT05086445** (2026-07-16) against your key-therapy ledger.
4. **Log AstraZeneca elecoglipron** (4 new Phase 3s, NCT07662044/109/135/213) into the trial tracker — new competitive entrant this window.
5. **Promote "emerging-therapy × Health Equity" gap cluster** (gaps #2, #3, #4, #6) to a candidate Tier 1 synthesis project; validate each pair with direct PubMed + Cochrane/PROSPERO searches to rule out terminology artifacts before committing.
6. **Housekeeping:** clean up the `.git/` lock-file debris (hundreds of stale `HEAD.lock.*` / `index.lock.*`).

---

*Automated review by diabetes-hub-monitor. Read-only run — no source files modified. Evidence levels follow RESEARCH_DOCTRINE.md; all new gap claims are BRONZE pending triple-source validation.*
